52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy

Key Takeaways Explain This Topic AI

Asthma is characterized by chronic airway inflammation, bronchial hyperresponsiveness, and variable airflow obstruction; diagnostic confirmation via spirometry requires demonstrating reversible airflow limitation, defined as a post-bronchodilator increase in FEV1 of >12% AND >200 mL following short-acting beta-2 agonist inhalation.

Bronchial provocation with methacholine demonstrating a provocative concentration causing a 20% fall in FEV1 (PC20) <=8 mg/mL confirms airway hyperresponsiveness and possesses a >95% negative predictive value to exclude asthma; fractional exhaled nitric oxide (FeNO) >=50 ppb in adults identifies eosinophilic / Type 2 airway inflammation responsive to inhaled corticosteroids.

Global Initiative for Asthma (GINA) guidelines strictly advise against SABA-only monotherapy in all adults and adolescents (>=12 years) due to down-regulation of beta-2 adrenergic receptors, loss of bronchoprotection, increased allergic inflammation, and significantly heightened risks of severe exacerbations and asthma-related mortality.

GINA Track 1 (Preferred Strategy) utilizes Single Maintenance and Reliever Therapy (SMART) with low-dose Inhaled Corticosteroid / Formoterol (ICS-Formoterol): formoterol delivers rapid bronchodilation within 1-3 minutes equivalent to albuterol with a 12-hour duration, ensuring immediate anti-inflammatory ICS administration with every symptom-driven puff.

Step 5 severe asthma warrants add-on long-acting muscarinic antagonists (LAMA, tiotropium Respimat) and targeted biologic therapies selected by phenotype: Omalizumab (anti-IgE) for severe allergic asthma, Mepolizumab/Benralizumab (anti-IL-5/5R) for severe eosinophilic asthma, Dupilumab (anti-IL-4R alpha) for eosinophilic or oral steroid-dependent asthma, and Tezepelumab (anti-TSLP) across allergic and non-eosinophilic T2-low phenotypes.

Last updated: September 2026

Pathophysiology & Airway Remodeling in Asthma

Asthma is a heterogeneous, chronic inflammatory disorder of the conducting airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and cough. The underlying pathophysiological hallmark is variable expiratory airflow limitation coupled with bronchial hyperresponsiveness (BHR) to direct and indirect environmental stimuli.

Cellular & Molecular Cascade

The classical paradigm involves Type 2 (T2-high) airway inflammation , driven by both adaptive and innate immune responses:

Allergen Sensitization & Dendritic Cell Presentation : Inhaled aeroallergens (e.g., house dust mites, animal dander, molds, pollens) breach the bronchial airway epithelium. Damaged epithelial cells release "alarmins"—specifically thymic stromal lymphopoietin (TSLP) , interleukin-33 (IL-33) , and interleukin-25 (IL-25) .

Th2 Lymphocyte & ILC2 Activation : Alarmins activate dendritic cells, which present antigen to naive CD4+ T cells, inducing differentiation into T-helper 2 (Th2) cells . Simultaneously, alarmins stimulate type 2 innate lymphoid cells (ILC2) in an antigen-independent fashion.

Key T2 Cytokine Mediators :

Interleukin-4 (IL-4) : Drives immunoglobulin class switching in B lymphocytes to produce immunoglobulin E (IgE) . IgE binds with high affinity to Fc-epsilon-RI receptors on mast cells and basophils.

Interleukin-5 (IL-5) : Governs eosinophil differentiation in the bone marrow, systemic mobilization, activation, and mucosal survival.

Interleukin-13 (IL-13) : Induces bronchial smooth muscle hyperreactivity, stimulates goblet cell metaplasia with mucus hypersecretion, impairs ciliary clearance, and stimulates epithelial nitric oxide synthase (iNOS) , which elevates fractional exhaled nitric oxide (FeNO).

Mast Cell Degranulation & Acute Bronchoconstriction : Cross-linking of allergen-specific IgE on sensitized mast cells triggers immediate degranulation, releasing preformed mediators ( histamine , tryptase) and newly synthesized lipid mediators ( cysteinyl leukotrienes LTC4, LTD4, LTE4 , and prostaglandin D2). These cause acute smooth muscle contraction, microvascular leakage, mucosal edema, and plasma exudation within minutes. IMMUNOPATHOGENESIS OF TYPE 2 (T2-HIGH) ASTHMA

• Aeroallergens / Environmental Insults ──► Airway Epithelium
• │
• Epithelial Alarmins: TSLP, IL-33, IL-25
• │
• ┌──────────────────────────────┴──────────────────────────────┐
• ▼ ▼
• Th2 CD4+ Lymphocytes ILC2
• │ │
• ┌────────────┼────────────┐ │
• ▼ ▼ ▼ │
• IL-4 IL-5 IL-13 ◄────────────────────────────────────────────┘
• │ │ │
• B-Cell IgE Eosinophil Goblet Cell Metaplasia,
• Synthesis Maturation Smooth Muscle Spasm,
• & Priming & Survival iNOS Induction (High FeNO)
• Airway Remodeling: The Cost of Chronic Uncontrolled Inflammation

When airway inflammation remains persistent and untreated by inhaled corticosteroids, progressive and irreversible structural changes occur, collectively termed airway remodeling :

Subepithelial Fibrosis : Thickening of the lamina reticularis with dense collagen deposition beneath the basement membrane.

Smooth Muscle Hypertrophy & Hyperplasia : Increased bronchial smooth muscle mass, which magnifies bronchoconstrictor responsiveness.

Goblet Cell Hyperplasia & Mucus Gland Hypertrophy : Hypersecretion of tenacious, mucin-rich mucus leading to extensive luminal mucus plugging, the primary cause of asphyxiation in fatal status asthmaticus.

Microvascular Proliferation : Angiogenesis and vessel dilation resulting in chronic airway wall thickening and edema.

Clinical Significance : Remodeling produces a fixed, non-reversible component of airflow obstruction that accelerates long-term FEV1 decline and mimics or overlaps with chronic obstructive pulmonary disease (COPD), known as Asthma-COPD Overlap (ACO).

Diagnostic Confirmation: Spirometry, Reversibility & Provocation Testing

The clinical diagnosis of asthma requires demonstrating two key features: a characteristic history of variable respiratory symptoms (wheeze, shortness of breath, chest tightness, cough) AND documented objective evidence of variable expiratory airflow limitation.

Diagnostic Spirometry & Bronchodilator Reversibility

Spirometry is the mandatory gold-standard investigation in all patients aged >=5 years suspected of having asthma:

Airflow Limitation : Defined as a reduced post-bronchodilator ratio of FEV1 to forced vital capacity (FEV1/FVC <0.70) or a ratio below the statistically derived Lower Limit of Normal (LLN) adjusted for age, sex, and height.

Bronchodilator Reversibility (BDR) Testing :

Spirometry is measured before and 10 to 15 minutes after administering a short-acting beta-2 agonist (typically 4 puffs of albuterol [400 mcg] via a pressurized metered-dose inhaler with a valved holding chamber).

Positive Reversibility Criterion : An increase in FEV1 of >12% AND >200 mL compared to baseline pre-bronchodilator measurements.

An increase in FEV1 of >15% and >400 mL provides virtually definitive confirmation of asthma over COPD. SPIROMETRIC BRONCHODILATOR REVERSIBILITY

% Improvement in FEV1 = [(Post-Bronchodilator FEV1 - Pre-Bronchodilator FEV1) / Pre-Bronchodilator FEV1] x 100

Diagnostic Requirement: BOTH >12% improvement AND >200 mL absolute volume increase

• Example: Baseline FEV1 = 2.00 L ──► Post-Albuterol FEV1 = 2.30 L
• Absolute Change: +300 mL (meets >200 mL threshold)
• Percentage Change: (0.30 L / 2.00 L) x 100 = 15.0% (meets >12% threshold)
• Interpretation: POSITIVE BRONCHODILATOR REVERSIBILITY CONFIRMED
• Alternative & Provocative Diagnostic Modalities

Normal baseline spirometry is common in asthmatic patients during asymptomatic intercritical intervals and does NOT exclude the diagnosis. When clinical suspicion remains high despite normal spirometry, advanced testing is indicated:

Bronchial Provocation (Methacholine Challenge Test) :

Inhalation of progressive concentrations of methacholine (a synthetic muscarinic cholinergic agonist that acts directly on airway smooth muscle M3 receptors).

Diagnostic Endpoint : The provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) .

Diagnostic Thresholds :

PC20 <=8 mg/mL (or <=16 mg/mL in some protocols): Confirms bronchial hyperresponsiveness.

PC20 >16 mg/mL : Negative test. Methacholine challenge has an extraordinarily high negative predictive value (>95%) ; a normal test in a patient currently experiencing symptoms virtually excludes active asthma.

Diurnal Peak Expiratory Flow (PEF) Variability :

Measured twice daily (morning upon rising and evening before bed) using a portable peak flow meter over 1 to 2 weeks.

Excessive Diurnal Variability : Daily variability >10% in adults (or >13% in children) supports an asthma diagnosis: Daily PEF Variability = PEF max ⁡ − PEF min ⁡ Mean of PEF max ⁡ and PEF min ⁡ × 100 \text{Daily PEF Variability} = \frac{\text{PEF}_{\max} - \text{PEF}_{\min}}{\text{Mean of } \text{PEF}_{\max} \text{ and } \text{PEF}_{\min}} \times 100 Daily PEF Variability = Mean of PEF m a x ​ and PEF m i n ​ PEF m a x ​ − PEF m i n ​ ​ × 100

Exercise Bronchoprovocation Testing :

Standardized 6-to-8 minute cycle ergometry or treadmill challenge.

A post-exercise fall in FEV1 of >10% AND >200 mL from pre-exercise baseline establishes the diagnosis of Exercise-Induced Bronchoconstriction (EIB).

Fractional Exhaled Nitric Oxide (FeNO) :

Non-invasive quantitative biomarker reflecting inducible nitric oxide synthase (iNOS) activity in bronchial epithelial cells driven by IL-13.

FeNO >=50 ppb in adults (>=35 ppb in children): Indicates active eosinophilic / Type 2 airway inflammation, strongly predicts symptomatic responsiveness to inhaled corticosteroid therapy, and serves as an objective marker of patient adherence.

FeNO <25 ppb : Eosinophilic inflammation is unlikely; prompts reconsideration of alternative diagnoses (e.g., vocal cord dysfunction, gastroesophageal reflux, heart failure).

Asthma Severity Classification vs. Asthma Control Assessment

Clinical guidelines distinguish between asthma severity (assessed prior to initiating controller therapy to determine starting treatment) and asthma control (assessed dynamically at every follow-up visit to guide stepwise titration). NAEPP / EPR-3 BASELINE ASTHMA SEVERITY CLASSIFICATION

(Assessed in patients NOT currently taking controller therapy)

Classification Daytime Symptoms Night Awakenings SABA Reliever Use Activity Limit FEV1 (% Pred) / FEV1/FVC

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

• Intermittent <= 2 days/week <= 2 times/month <= 2 days/week None FEV1 > 80%; Normal ratio
• Mild Persistent > 2 days/week, 3 to 4 times/month > 2 days/week, Minor limitation FEV1 >= 80%; Normal ratio
• not daily not daily
• Moderate Persistent Daily > 1 time/week, Daily Some limitation FEV1 60-80%; Ratio reduced 5%
• not nightly

Severe Persistent Throughout day Often 7 nights/week Several times/day Extremely limited FEV1 < 60%; Ratio reduced >5%

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Longitudinal Assessment of Asthma Control (GINA Criteria)

At every clinical encounter, asthma control over the preceding 4 weeks must be evaluated across two independent domains: symptom control and future risk of adverse outcomes.

The Four GINA Symptom Control Criteria :

Daytime asthma symptoms occurring more than twice per week ?

Any nighttime awakening due to asthma symptoms or coughing?

SABA or reliever inhaler needed for symptoms more than twice per week (excluding prophylactic use before exercise)?

Any activity limitation due to asthma (e.g., walking, exercising, playing)?

Grading of Symptom Control :

Well-Controlled : None (0) of the four criteria present.

Partly Controlled : 1 or 2 of the criteria present.

Uncontrolled : 3 or 4 of the criteria present.

Important

THE EXACERBATION INDEPENDENCE RULE Regardless of symptom scores, any patient who has experienced >=1 severe exacerbation requiring systemic corticosteroids or hospitalization in the past 12 months is automatically classified as having high future risk of exacerbation , warranting immediate treatment review and stepping up of controller therapy.

The Paradigm Shift in GINA Guidelines: Eliminating SABA Monotherapy

For over five decades, clinical guidelines recommended initiating treatment for intermittent asthma with as-needed short-acting beta-2 agonist (SABA, e.g., albuterol) monotherapy. However, landmark clinical trials and epidemiological investigations led to a historic paradigm shift: The Global Initiative for Asthma (GINA) no longer recommends SABA-only treatment for any adult or adolescent aged >=12 years.

Pathophysiological Rationale for Abandoning SABA Monotherapy

Treating Symptoms While Ignoring Inflammation : SABA monotherapy rapidly relieves bronchospasm through smooth muscle relaxation but possesses zero anti-inflammatory activity. Leaving chronic mucosal inflammation untreated permits progressive airway remodeling and uninhibited mucosal edema.

Beta-2 Adrenergic Receptor Down-Regulation : Regular or frequent SABA use (even as brief as 1 to 2 weeks) induces rapid phosphorylation, internalization, and down-regulation of cell-surface beta-2 adrenergic receptors. This results in:

Progressive tolerance and loss of bronchoprotection against bronchoconstrictor stimuli.

Rebound airway hyperresponsiveness upon bronchodilator withdrawal.

Blunting of the acute bronchodilator response during a catastrophic asthma exacerbation.

Augmentation of Allergic Inflammation : Beta-agonist monotherapy increases mast cell degranulation, promotes eosinophilic recruitment into bronchial tissues, and upregulates pro-inflammatory cytokines.

Epidemiological Risk & Mortality :

Dispensing >=3 canisters of SABA per year (equivalent to roughly daily use) is independently associated with a marked increase in emergency department visits and severe exacerbations.

Dispensing >=12 canisters of SABA per year (>=1 canister per month) is directly associated with a dramatically increased risk of asthma-related death .

Crucially, up to 16% to 20% of patients dying from acute fatal asthma attacks had mild, intermittent symptoms and were managed exclusively with SABA monotherapy.

GINA Stepwise Management Tracks: Track 1 (SMART) vs. Track 2

GINA stratifies pharmacotherapy for adults and adolescents (>=12 years) into two parallel tracks:

Track 1 (Preferred) : Reliever is as-needed low-dose ICS-formoterol (Single Maintenance and Reliever Therapy, SMART / MART).

Track 2 (Alternative) : Reliever is as-needed SABA , paired with regular daily maintenance ICS or ICS-LABA. GINA STEPWISE TREATMENT TRACKS (AGES >=12 YEARS)

• Step Track 1 (Preferred: ICS-Formoterol Reliever) Track 2 (Alternative: SABA Reliever)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Step 1 As-needed low-dose ICS-formoterol Take low-dose ICS whenever SABA taken
• (for symptom relief alone; no daily baseline)

• Step 2 As-needed low-dose ICS-formoterol Daily low-dose maintenance ICS
• (same as Step 1) + as-needed SABA reliever

• Step 3 Low-dose maintenance ICS-formoterol Daily low-dose maintenance ICS-LABA
• + as-needed low-dose ICS-formoterol (SMART) + as-needed SABA reliever

• Step 4 Medium-dose maintenance ICS-formoterol Daily medium/high-dose maintenance ICS-LABA
• + as-needed low-dose ICS-formoterol (SMART) + as-needed SABA reliever

• Step 5 High-dose maintenance ICS-formoterol + LAMA; High-dose maintenance ICS-LABA + LAMA;
• Phenotypic workup for targeted biologic therapy Phenotypic workup for targeted biologic therapy
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• The Biophysics of Formoterol in SMART Therapy

Why is formoterol the only long-acting beta-2 agonist (LABA) approved for SMART therapy, whereas salmeterol and vilanterol cannot be used as relievers?

Onset of Bronchodilation : Formoterol is a moderately lipophilic compound that rapidly enters the plasma membrane outer leaflet, interacting with the beta-2 receptor within 1 to 3 minutes —a rapid onset of action identical to albuterol .

Duration of Action : Formoterol remains embedded in the cell membrane lipid bilayer, providing sustained bronchodilation for 12 hours .

Safety Profile : Formoterol is a full/high-intrinsic efficacy agonist with a wide therapeutic window, allowing repeated doses during an acute exacerbation without excessive receptor tachyphylaxis.

The Synergy of SMART : In a single inhaler (e.g., budesonide-formoterol 160/4.5 mcg or beclomethasone-formoterol 100/6 mcg), every symptom that prompts a puff of formoterol simultaneously delivers an immediate anti-inflammatory burst of budesonide. This suppresses the nascent inflammatory surge before it escalates into a severe exacerbation.

Maximum Daily Dose : The recommended maximum formoterol dose is 72 mcg in 24 hours (equivalent to 12 total puffs of budesonide-formoterol 160/4.5 mcg per day, including maintenance and reliever doses).

Targeted Biologic Therapies for Severe Uncontrolled Asthma (Step 5)

Patients with persistent symptoms or exacerbations despite optimized high-dose ICS-LABA and LAMA therapy require phenotypic biomarker evaluation to guide targeted biologic selection: TARGETED BIOLOGIC AGENTS FOR SEVERE STEP 5 ASTHMA

Agent Molecular Target Key Biomarkers / Indications Dosing & Clinical Notes

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

• Omalizumab Anti-IgE monoclonal Total IgE 30-1500 IU/mL; Positive skin Subcutaneous q2-4w based on
• antibody (binds Fc) prick test / specific IgE to perennial weight and baseline IgE;
• aeroallergen (dust mite, dander, mold) Black box: Anaphylaxis (0.2%)

• Mepolizumab Anti-IL-5 cytokine Blood eosinophils >= 150-300 cells/uL; 100 mg SC every 4 weeks;
• Recurrent eosinophilic exacerbations Reduces exacerbations by ~50%

• Benralizumab Anti-IL-5 Receptor Blood eosinophils >= 150-300 cells/uL; 30 mg SC q4w for 3 doses, then
• alpha (IL-5Rα) Induces NK cell antibody-dependent every 8 weeks; near-complete
• cellular cytotoxicity (ADCC) of eosinophils tissue eosinophil depletion

• Dupilumab Anti-IL-4 Receptor Blood eosinophils >= 150-300 cells/uL OR 200 or 300 mg SC q2w;
• alpha (blocks IL-4 FeNO >= 25 ppb; Steroid-dependent asthma; Indicated for severe asthma,
• and IL-13 signaling) Comorbid severe eczema or nasal polyposis atopic dermatitis, CRSwNP

• Tezepelumab Anti-TSLP (thymic Broadest indication: Effective in BOTH 210 mg SC every 4 weeks;
• stromal lymphopoietin) T2-high (eosinophilic) AND T2-low Blocks upstream alarmin cascade
• (non-eosinophilic) severe asthma independent of IgE/eosinophils

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Inhaler Technique Counseling & Written Asthma Action Plans

Suboptimal inhaler technique and non-adherence account for over 70% of poorly controlled asthma cases in clinical practice.

Metered-Dose Inhalers (MDI) vs. Dry Powder Inhalers (DPI)

Pressurized MDIs (pMDI) :

Require hand-breath coordination. Actuation without a spacer results in up to 80% to 90% of the medication depositing in the oropharynx, with only 10% to 15% reaching the pulmonary bed.

Valved Holding Chamber (Spacer) : Mandated for all pMDIs. Slows aerosol velocity, allows large aerosol droplets to settle on chamber walls, and dramatically increases intrapulmonary deposition to >30% to 40%.

Inhalation Technique: Exhale completely away from device; place lips tightly around mouthpiece; actuate once; inhale slowly and deeply over 3 to 5 seconds ; hold breath for 10 seconds (or as long as comfortable).

Dry Powder Inhalers (DPI, e.g., Turbuhaler, Diskus, Ellipta) :

Breath-actuated; medication micronized into lactose carrier particles.

Inhalation Technique: Exhale fully away from device; place mouthpiece in mouth; inhale rapidly, forcefully, and deeply from the very beginning of the breath to generate the turbulent kinetic energy needed to de-aggregate powder particles. Never use a spacer with a DPI.

Adverse Effects & Mouth Rinsing :

Oropharyngeal candidiasis (thrush) and dysphonia (secondary to steroid-induced laryngeal myopathy) occur with all ICS formulations.

Prevention: Always rinse mouth and gargle thoroughly with water and spit out (never swallow) immediately following every dose of an inhaled corticosteroid.

The Written Asthma Action Plan

Every patient with asthma must receive an individualized, written Asthma Action Plan based on symptom recognition and/or Peak Expiratory Flow (PEF) personal best:

Green Zone (80% to 100% of Personal Best PEF) :

Clinical Status: No cough, wheeze, or dyspnea; sleeping through the night; normal activity.

Action: Continue standard daily maintenance controller regimen.

Yellow Zone (50% to 79% of Personal Best PEF) :

Clinical Status: Presence of cough, mild wheeze, nighttime waking, chest tightness, or reduced exercise tolerance; early sign of viral upper respiratory tract infection.

Action: Escalate reliever therapy immediately:

In Track 1 (SMART): Take 1 additional puff of low-dose ICS-formoterol as needed for symptoms (up to maximum 12 total puffs/day).

In Track 2: Take 2 to 4 puffs of SABA every 20 minutes for up to 1 hour; temporarily quadruple or double maintenance ICS for 7 to 14 days.

If symptoms or PEF fail to return to Green Zone within 24 to 48 hours : Initiate a short course of oral corticosteroids (prednisone 40 to 50 mg daily for 5 to 7 days) and contact the physician.

Red Zone (<50% of Personal Best PEF) :

Clinical Status: Severe dyspnea, difficulty speaking in full sentences, intercostal retractions, cyanosis, or lack of response to yellow zone escalation.

Action: Medical Emergency . Inhale immediate high-dose reliever (4 to 6 puffs albuterol or 2 puffs ICS-formoterol), take oral prednisone 40 to 50 mg immediately, and activate emergency medical services (call 911) or proceed to the nearest emergency department .

Loading diagram... GINA Track 1 (SMART) Stepwise Treatment Pathway for Adults and Adolescents